Active — Not RecruitingPhase 3

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

China108 participantsStarted 2025-04-15

Plain-language summary

The goal of this clinical trial is to evaluate the efficacy and safety of NRT6003 Injection compared to cTACE in patients with unresectable HCC.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Diagnosed as hepatocellular carcinoma (CNLC Ⅰa-Ⅲa) clinically, by imaging and/or pathology based on the guideline of the National Health Commission of the People's Republic of China (2024).
. Evaluated by the investigator as not suitable for surgical resection/ablation/liver transplantation, or there is high risk for surgical resection, or the participant refuses surgical resection/ablation/liver transplantation.
. Child-Pugh score ≤ 7.
. Eastern Cooperative Oncology Group performance status ≤ 1.
. Adequate organ function.

Exclusion criteria

. Imaging evidence or suspicion of extrahepatic metastases (including regional lymph node metastases).
. Prior antitumor treatment for primary hepatocellular carcinoma.
. Prior external radiation therapy or intra-arterial brachytherapy.
. Liver vascular evaluation results that do not meet all the requirements of the study.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Time to Progression (TTP)

Timeframe: Through study completion, at least 18 months

Trial details

NCT IDNCT06900543

SponsorChengdu New Radiomedicine Technology Co. LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-10

View on ClinicalTrials.gov More Unresectable Hepatocellular Carcinoma trials